Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval

Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.